Results 181 to 190 of about 201,990 (292)

The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia

, 2018
Michael Davidson
openalex   +1 more source

Neural Correlates of Cognitive Improvement After Virtual Reality‐Based Cognitive Remediation in Psychosis and Mood Disorders: A Randomized Controlled Trial

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Cognitive impairment in mood disorders and schizophrenia spectrum disorders hampers patients' clinical and functional outcomes. A key challenge in pro‐cognitive treatment development is the limited insight into the underlying neurocircuitry correlates of cognitive changes.
Viktoria Damgaard, Andreas Elleby Jespersen, Ida Kruse Søndergaard, Anders Lumbye, Maj Vinberg, Louise Birkedal Glenthøj, Merete Nordentoft, Anjali Sankar, Gitte Moos Knudsen, Julian Macoveanu, Kamilla Woznica Miskowiak   +10 more
wiley   +1 more source

Safety outcomes of trazodone versus antipsychotics for delirium after hospital admission in adults aged 65 years and older: a nationwide cohort study using a target trial emulation framework. [PDF]

Lancet Healthy Longev
Yang CT, Wilkins JM, Pritchard KT, Chen Q, Liu X, Kim DH, Lin KJ.   +6 more
europepmc   +1 more source

Cognitive and Psychomotor Processing Speed in Medication‐Naïve Individuals With First‐Episode of Psychosis: The Role of Peripheral Inflammatory Markers

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background and Hypothesis Deficits in processing speed (PS) and psychomotor speed (PMS) are core cognitive impairments in schizophrenia spectrum disorders, including first‐episode psychosis (FEP). Neuroinflammation has been proposed as a potential contributor to these deficits.
Ángel Yorca‐Ruiz, Carlos Martínez Asensi, Rebeca Magdaleno Herrero, Alexandre Díaz‐Pons, Víctor Ortiz‐García de la Foz, Luis Manuel Fernández Cacho, Ana Catalán Alcantara, Benedicto Crespo‐Facorro, Rosa Ayesa‐Arriola   +8 more
wiley   +1 more source

Clozapine Therapy With or Without Antipsychotic Augmentation: A Retrospective Evaluation of Prescribing Practices in a Canadian Provincial Residential Treatment Centre for Concurrent Disorders: Traitement par la clozapine avec ou sans intensification à l'aide d'antipsychotiques : évaluation rétrospective des pratiques de prescription dans un centre de traitement résidentiel provincial canadien pour les troubles concomitants. [PDF]

Can J Psychiatry
Frankow L, Bousman CA, Mathew N, Rafizadeh R.   +3 more
europepmc   +1 more source

Cerebral Computed Tomographic Findings in Schizophrenia: Relationship to Second-Generation Antipsychotics and Hyperprolactinemia [PDF]

Paula Simina Petric, Petru Ifteni, Andreea Violeta Popa, Andreea Teodorescu   +3 more
openalex   +1 more source

Cost-Offsets of New Medications for Treatment of Schizophrenia [PDF]

Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia.
Richard G. Frank, Sharon-Lise Normand, Thomas G. McGuire   +2 more
core  

Associations Between Cognitive Functions and Subsequent Mood Disorder Prognosis in Low‐Risk, High‐Risk and Affected Monozygotic Twins: A Seven‐Year Follow‐Up Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Aberrant cognition is common among individuals at familial risk for mood disorders (MD) and those already affected. However, long‐term prospective studies are needed to determine whether specific cognitive features predict illness onset and relapse; and whether cognitive impairments reflect neurodevelopmental traits or ...
Kamilla Miskowiak, Hanne Lie Kjærstad, Stella Lystlund, Anjali Sankar, Lars Kessing, Maj Vinberg   +5 more
wiley   +1 more source

Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom? [PDF]

Schizophrenia (Heidelb)
Correll CU, Rubio JM, Kane JM.
europepmc   +1 more source

Preclinical Neurochemical and Electrophysiological Profile of 1192U90, A Potential Antipsychotic [PDF]

, 1996
Stacey A. Jones‐Humble
openalex   +1 more source